Age-related Macular Degeneration Market Size, Growth, Trends | Report 2022-2030

The global age-related macular degeneration market was surpassed at USD 9.92 billion in 2021 and is expected to hit around USD 18.34 billion by 2030, growing at a CAGR of 7.07% from 2022 to 2030.

Report Highlights

• The eylea segment dominated the market in 2021 with a revenue share of over 50.2%. 
• The wet AMD segment dominated the market in 2021 with a revenue share of 100%. 
• The hospital pharmacy segment dominated the global market in 2021 with a revenue share of over 50.08%. 
• North America dominated the market in 2021 with a revenue share of over 50.5%. 

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39571

The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

Among wet (exudative) and dry (atrophic) age-related macular degeneration, dry AMD is a more prevalent eye disease with 85-90% of cases causing vision damage due to excessive drusen development in the retina. National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.’s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche’s Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company’s biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Scope of The Report

Product Insights

The eylea segment dominated the market in 2021 with a revenue share of over 50.2%. This dominance can be attributed to high market penetration and patent protection. In addition, according to research studies, patients receiving Beovu reported four times more intraocular inflammation than those on Eylea. Such factors boost the adoption of Eylea over the novel drug Beovu. Followed by Eylea, Lucentis is expected to hold the largest market share over the coming years owing to factors such as the launch of a new drug delivery system. In October 2021, F. Hoffmann La Roche Ltd.’s product Susvimo, which is a refillable implant for Lucentis, obtained U.S. FDA approval. Susvimo requires refilling with ranibizumab once in six months. This will decrease the frequency of administration, thus addressing the unmet need of patients.

Beovu is anticipated to witness the fastest growth over the forecast period owing to the patent protection, superior drying efficacy, and positive results in the treatment of severe cases of wet AMD. However, the product has been found to be associated with concomitant vascular occlusion, retinal vasculitis, intraocular inflammation, and irreparable vision loss in patients. Due to these serious adverse effects, the sales of the product may be affected in the coming years if the company does not introduce an innovative approach to avoid or reduce these adverse reactions.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39571

Disease Type Insights

The wet AMD segment dominated the market in 2021 with a revenue share of 100%. nAMD accounts for more than 10-15% of macular degeneration-related vision loss cases across the globe. Lucentis, Eylea, and Beovu are the major drugs approved for the treatment of wet age-related macular degeneration. Novartis’ Beovu, a long-acting anti-VEGF, was approved by the U.S. FDA in October 2019. However, the unfavorable side effects of this drug, such as retinal vasculitis, will limit its broader uptake.

Dry AMD is anticipated to witness the fastest growth over the forecast period owing to the expected launch of promising product candidates by 2023 and the disease burden of dry AMD. Dry AMD accounts for 85-90% of all macular degeneration cases. The management of dry macular degeneration is currently limited to vitamin formulations. Various novel therapeutic options for its treatment are currently in the clinical pipeline such as Luminate, Zimura, and Intravitreal pegcetacoplan. The approval of these potential candidates may fuel the growth of the dry AMD segment in the coming years.

Distribution Channel Insights

The hospital pharmacy segment dominated the global market in 2021 with a revenue share of over 50.08%. This dominance can be attributed to the rise in the prevalence of age-related macular degeneration (AMD) and hospitalization for the treatment. According to the Royal National Institute of Blind People (RNIB), around 25.3 million people were at high risk of developing age-related macular degeneration (AMD) in 2020. The majority of patients are treated by using various medications such as Lucentis, Eylea, and Beovu, which are administrated intravenously under the supervision of experienced physicians in hospitals. Thus, increasing demand for AMD treatment is anticipated to increase hospital visits, thereby driving the market.

The specialty pharmacy segment is expected to witness the fastest growth over the forecast period due to the ease of drug availability and reimbursement coverage offered by specialty pharmacies. For instance, CVS Caremark offers Eylea, Lucentis, Avastin, and Beovu prescription coverage to eligible retirees and employees who are enrolled in the Public Employees Insurance Program (PEIP) program. This initiative is expected to fuel segment growth.

Regional Insights

North America dominated the market in 2021 with a revenue share of over 50.5%. This dominance can be attributed to the increasing prevalence of AMD. According to the American Academy of Ophthalmology, around 15 million North Americans live with AMD. Europe held the second-largest market share in 2021. This is due to the high prevalence of macular degeneration in Europe, which is estimated to rise by around 20% until 2050.

Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the high geriatric population and disease burden. The favorable government initiatives to support the affordability of costly anti-VEGF products may contribute to the market growth. Lucentis and Eylea were added to the National Reimbursement Drug List (NRDL) in China in 2017 and 2019.

Key Players

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Amgen Inc.
• Biogen
• Samsung Bioepis

Market Segmentation

• By Product Outlook
  • Eylea
  • Lucentis
  • Beovu
  • Others
• By Disease Type Outlook
  • Dry AMD
  • Wet AMD
• By Distribution Channel Outlook
  • Hospital Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy
• By Regional Outlook
  • North America

• • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39571

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333